株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の子宮内膜症市場

Endometriosis

発行 Global Industry Analysts, Inc. 商品コード 236863
出版日 ページ情報 英文 160 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
世界の子宮内膜症市場 Endometriosis
出版日: 2016年10月01日 ページ情報: 英文 160 Pages
概要

当レポートでは、世界の子宮内膜症市場について調査し、市場の概要と地域別、用途別市場動向、2022年までの予測、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • 子宮内膜症の概要
    • 市場概要
    • 既存薬の有効性および安全性の低いプロファイルが医療のアンメットニーズに
    • 上市されている子宮内膜症治療薬
    • パイプラインレビュー
    • パイプラインにおける主要な子宮内膜症治療薬:2016年
    • 現在および将来分析
    • 子宮内膜症および子宮内膜癌の新興の治療法
    • 世界の認知度キャンペーンと努力
  • 子宮内膜症とその治療法:概要
    • イントロダクション
    • 女性の子宮内膜症発生
    • 原因と症状
    • 子宮内膜症の種類 他
  • 子宮内膜症の治療
    • 非ステロイド抗炎症性薬(NSAID)
    • 非ホルモン治療
    • 手術
    • 補足治療
  • 治験/製品革新/認可
  • 技術進歩
  • 近年の業界活動
  • 主要企業
    • AbbVie Inc.
    • AEterna Zentaris Inc.
    • アステラス製薬株式会社
    • AstraZeneca Plc.
    • Bayer HealthCare Pharmaceuticals, Inc.
    • Debiopharm Group
    • Evotec AG
    • キッセイ薬品工業株式会社
    • Neurocrine Biosciences, Inc.
    • ObsEva SA
    • Pfizer, Inc.
    • Repros Therapeutics, Inc.
    • Roivant Sciences Ltd)
    • 武田薬品工業株式会社
    • ValiRx Plc
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
  • アジア太平洋地域
  • その他の諸国

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-6433

This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 38 companies including many key and niche players such as -

AbbVie Inc.
AEterna Zentaris Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer HealthCare Pharmaceuticals, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Endometriosis Statistics Fact Sheet
  • A Quick Market Primer
  • Poor Efficacy and Safety Profiles of Existing Drugs Lead to Unmet Medical Needs
  • Key Endometriosis Drugs on the Market
    • Table 1: Leading Endometriosis Drugs on the Market (2015): Percentage Market Share Breakdown of Depo Provera, Eligard, Lupron, Visanne, Zoladex, and Others (includes corresponding Graph/Chart)
  • The Pipeline Review
  • Key Endometriosis Drugs in the Pipeline: 2016
  • Current and Future Analysis
  • Emerging Treatment for Endometriosis & Endometrial Cancer
  • Global Awareness Campaigns and Efforts

2. ENDOMETRIOSIS & ITS TREATMENT - AN OVERVIEW

  • Introduction
  • Occurrence of Endometriosis in Women
  • Causes and Symptoms
  • Causes
    • Estrogen Theory
    • Mullerianosis Theory
    • Retrograde Menstruation Theory
    • Coelomic Metaplasia Theory
    • Hereditary Factors
    • Environmental Factors
      • Dioxin Behavior in the Body
    • Birth Defects
    • Other Causes
  • Symptoms of Endometriosis
    • Reasons for Pain due to Endometriosis
    • Endometriosis and Infertility
  • Kinds of Endometriosis
  • Reproductive Area Endometriosis
  • Uterosacral/Presacral Nerve Endometriosis
  • Cul-de-Sac ("Pouch of Douglas") Endometriosis
  • Gastrointestinal Endometriosis
  • Pleural (lung/chest cavity/diaphragmatic) Endometriosis
  • Urinary Tract (kidneys, ureters, bladder and urethra) Endometriosis
  • Skin Endometriosis
  • Sciatic Endometriosis
  • Stages of Endometriosis
  • Diagnosis of Endometriosis
  • Major Diagnostic Techniques
  • Pelvic Exam
  • Laparoscopy
  • Other Diagnostic Procedures
  • A New Non-invasive Test for the Diagnosis of Endometriosis
  • Endometriosis Markers
  • Counseling of patients
  • Recurrence of Endometriosis
  • Endometriosis & Infertility
  • Miscarriage
  • Endometriosis & Thyroid Autoimmunity
  • Relationship between Endometriosis and Autoimmune Disease
  • Endometriosis & Cancer
  • Associations & Research Centers
  • The Endometriosis Association
  • Endometriosis Research Center

3. TREATMENT OF ENDOMETRIOSIS

  • Endometriosis & Available Treatment Options
  • Endometriosis Treatment: In a Nutshell

I. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

  • II. Hormonal Therapy
  • Gonadotropin Releasing Hormone (Gnrh) Agonists
    • Select Major GnRH-Agonists for Endometriosis Treatment
    • Lupron, Zoladex and Synarel - The Major Drugs
    • Abbott's Lupron(r) (Leuprorelin)
    • AstraZeneca's Zoladex(r) (Goserelin)
    • Pfizer's Synarel (Nafarelin Acetate)
  • Add-back Medication
  • Progestogens
    • Select Major Progestins for Endometriosis Treatment
    • Combined Oral Contraceptive Pill
    • Danazol and Other Suppressive Steroids
  • Chinese Herbs - More Effective than Danazol or Gestrinone
  • Aromatase Inhibitors

III. Non-hormonal Therapy

  • Anti-Angiogenic Agents
  • Selective COX-2 Inhibitors
  • TNF-Alpha Inhibitors

IV. Surgical Techniques

V. Complementary Therapies

  • Long-term Approach to Pain
  • Lifestyle Modifications
  • Chinese Herbs
  • Treatment for Endometriosis-related Infertility
  • Hormonal Treatment
    • Minimal to Mild Endometriosis
    • Moderate-Severe Endometriosis
  • Surgical Treatment
    • Minimal-Mild Endometriosis
    • Moderate-Severe Endometriosis
  • Treatment for Ovarian Endometriosis
  • Surgical Vs. Medicinal Interventions
    • Medicinal Interventions
      • Advantages
      • Disadvantages
    • Surgery
      • Advantages
      • Disadvantages
  • In-vitro Fertilization
  • Other Treatment

4. SELECT CLINICAL TRIALS/PRODUCT INNOVATIONS & APPROVALS

  • Virexxa Receives FDA Clearance to Proceed to Phase II
  • OBE2109 by ObsEva Receives IND Clearance
  • Galena Biopharma Presents Phase 1/2a Data on Endometrial Cancer Immunotherapies
  • AbbVie and Neurocrine Report Positive Phase 3 Trial Data of Elagolix
  • ValiRx Plc to Begin Endometriosis Clinical Research with its VAL201
  • Aurobindo Pharma Receives FDA Approval to Market Tablets for Endometriosis Treatment
  • Lumenis to Introduce UltraPulse DUO CO2 laser system and FemTouch Solution
  • Bayer Launches Phase II Trials of vilaprisan for Endometriosis Treatment
  • Nippon Shinyaku Conducts Phase I Evaluation of NS 580 for Endometriosis Therapy
  • Teleflex to Showcase its Surgical Solutions for Endometriosis
  • ValiRx Plc Receives Patent Grant for VAL201
  • Hologic Launches NovaSure 6mm Endometrial Ablation System
  • Endometriosis Research Foundation Releases Standardized Data Tools
  • ESHRE Develops App for Endometriosis Management

5. RECENT INDUSTRY ACTIVITY

  • Takeda and Roivant Partner to Form Myovant
  • Evotec-Bayer Collaboration Reaches Important Clinical Milestones for Endometriosis Therapy
  • ObsEva and Kissei Pharmaceutical Enter Into Collaboration Agreement for KLH-2109
  • Aeterna Zentaris Adds New Clinical Site for Endometrial Cancer Therapy Phase 3 Trial
  • VolitionRx Enters Into Collaboration with University of Oxford for Endometriosis Clinical Solution
  • SRI International and Nobelpharma Enter Into Licensing Agreement for SR16234

6. FOCUS ON SELECT GLOBAL PLAYERS

  • AbbVie Inc. (US)
  • AEterna Zentaris Inc. (Canada)
  • Astellas Pharma Inc. (Japan)
  • AstraZeneca Plc. (UK)
  • Bayer HealthCare Pharmaceuticals, Inc. (US)
  • Debiopharm Group (Switzerland)
  • Evotec AG (Germany)
  • Kissei Pharmaceutical Co., Ltd. (Japan)
  • Neurocrine Biosciences, Inc. (US)
  • ObsEva SA (Switzerland)
  • Pfizer, Inc. (US)
  • Repros Therapeutics, Inc. (US)
  • Roivant Sciences Ltd. (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • ValiRx Plc (UK)

7. GLOBAL MARKET PERSPECTIVE

    • Table 2: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 3: World Historic Review for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 4: World 14-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • United States: The Largest Market for Endometriosis
    • Endometriosis Associations Increase Awareness
    • Newer Diagnostic Methods Yet to Expand Across the Country
    • Key Endometriosis Drugs on the Market
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 5: The US Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 6: The US Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Select Key Players
  • B. Market Analytics
    • Table 7: Canadian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 8: Canadian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Clinical Trial
    • Select Key Players
  • B. Market Analytics
    • Table 9: Japanese Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 10: Japanese Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

  • Market Analysis
    • Table 11: European Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 12: European Historic Review for Endometriosis Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 13: European 14-Year Perspective for Endometriosis Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Programmes to Maintain Endometriosis Database
  • B. Market Analytics
    • Table 14: French Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 15: French Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Clinical Trial
    • Strategic Corporate Development
    • Evotec Ag - A Key Player
  • B. Market Analytics
    • Table 16: German Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 17: German Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 18: Italian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 19: Italian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Product Launches
    • Select Key Players
  • B. Market Analytics
    • Table 20: The UK Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 21: The UK Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 22: Spanish Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 23: Spanish Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • A. Market Analysis
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 24: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 25: Rest of Europe Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Proteomics Being Researched for Endometriosis Therapeutics (Australia)
    • Select Key Player
  • B. Market Analytics
    • Table 26: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 27: Asia-Pacific Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Product Launch
  • B. Market Analytics
    • Table 28: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 29: Rest of World Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top